ZFIN ID: ZDB-FISH-150901-6585
Fish name: f1Tg
Genotype: f1Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by f1Tg
Human Disease Conditions Citations
congestive heart failure chemical treatment by environment: aristolochic acid Lam et al., 2012
GENE EXPRESSION
Gene expression in f1Tg
PHENOTYPE
Phenotype in f1Tg
Phenotype Conditions Figures
atrium elongated, abnormal chemical treatment by environment: doxorubicin Fig. 1 from Liu et al., 2014
cardiac muscle cell decreased amount, abnormal surgical manipulation: cardiac ventricle, chemical treatment: alvocidib Fig. 7 from Matrone et al., 2015
cardiac muscle cell decreased amount, abnormal chemical treatment: alvocidib Fig. 7 from Matrone et al., 2015
cardiac muscle cell proliferation increased occurrence, abnormal chemical treatment by environment: 6-bromoindirubin-3'-oxime, chemical treatment by environment: aristolochic acid Fig. 5 with image from Kim et al., 2016
cardiac muscle contraction process quality, abnormal surgical manipulation: cardiac ventricle, chemical treatment: alvocidib Fig. 7 from Matrone et al., 2015
cardiac muscle contraction process quality, abnormal chemical treatment: alvocidib Fig. 3 with image from Matrone et al., 2015
cardiac muscle tissue regeneration decreased occurrence, abnormal surgical manipulation: cardiac ventricle, chemical treatment: alvocidib Fig. 7 from Matrone et al., 2015
cardiac muscle tissue regeneration decreased process quality, abnormal resection: cardiac ventricle, chemical treatment: 4-methylumbelliferone Fig. 2 from Missinato et al., 2015
cardiac ventricle collapsed, abnormal chemical treatment by environment: doxorubicin Fig. 1 from Liu et al., 2014
cardiac ventricle decreased size, abnormal chemical treatment by environment: aristolochic acid Fig. 5 with image from Kim et al., 2016
cardiac ventricle decreased size, abnormal chemical treatment by environment: aristolochic acid, chemical treatment by environment: lithium chloride Fig. 5 with image from Kim et al., 2016
cardiac ventricle size, ameliorated chemical treatment by environment: 6-bromoindirubin-3'-oxime, chemical treatment by environment: aristolochic acid Fig. 5 with image from Kim et al., 2016
cardiac ventricle cardiac muscle cell decreased amount, abnormal chemical treatment: alvocidib Fig. 5 with image from Matrone et al., 2015
cardiac ventricle cardiac muscle cell proliferation decreased occurrence, abnormal chemical treatment: alvocidib Fig. 5 with image from Matrone et al., 2015
heart decreased size, abnormal chemical treatment: alvocidib Fig. 3 with image from Matrone et al., 2015
heart edematous, abnormal chemical treatment by environment: aristolochic acid Fig. 1 with image from Lam et al., 2012
heart has fewer parts of type cardiac muscle cell, abnormal chemical treatment by environment: aristolochic acid Fig. 2 with imageFig. 6 with image from Lam et al., 2012
heart morphology, abnormal chemical treatment by environment: aristolochic acid Fig. 1 with image from Lam et al., 2012
heart morphology, ameliorated chemical treatment by environment: visnagin, chemical treatment by environment: doxorubicin Fig. 1 from Liu et al., 2014
heart morphology, ameliorated chemical treatment by environment: doxorubicin, chemical treatment by environment: 1,3-diphenylurea Fig. 1 from Liu et al., 2014
heart contraction decreased rate, abnormal chemical treatment by environment: doxorubicin Fig. 1Fig. SMovie2 from Liu et al., 2014
heart contraction process quality, abnormal chemical treatment by environment: aristolochic acid Fig. 1 with image from Lam et al., 2012
heart contraction rate, ameliorated chemical treatment by environment: doxorubicin, chemical treatment by environment: 1,3-diphenylurea Fig. 1 from Liu et al., 2014
heart contraction rate, ameliorated chemical treatment by environment: visnagin, chemical treatment by environment: doxorubicin Fig. 1Fig. SMovie3 from Liu et al., 2014
pericardium edematous, abnormal chemical treatment by environment: doxorubicin Fig. 1 from Liu et al., 2014
whole organism gata4 expression decreased amount, abnormal chemical treatment: alvocidib Fig. 6 from Matrone et al., 2015
whole organism Ab3-polr2a labeling decreased amount, abnormal chemical treatment: alvocidib Fig. 2 from Matrone et al., 2015
whole organism gata6 expression increased amount, abnormal chemical treatment: alvocidib Fig. 6 from Matrone et al., 2015
whole organism ab3-cdk9 labeling increased amount, abnormal chemical treatment: alvocidib Fig. 2 from Matrone et al., 2015
whole organism gata5 expression increased amount, abnormal chemical treatment: alvocidib Fig. 6 from Matrone et al., 2015
whole organism gata4 expression increased amount, abnormal chemical treatment: alvocidib Fig. 6 from Matrone et al., 2015
whole organism viability, abnormal chemical treatment by environment: aristolochic acid Fig. 1 with image from Lam et al., 2012

CITATIONS  (52)